Last week, 24th-25th August 2021 took place the 1st Neuropathic Pain Therapeutics Summit where our Head of Discovery & Preclinical R&D- Ion Channel Target in Pain Daniela Papadia has taken part as an Expert Speaker.
It was an aspiring meeting which had an ambitious objective of discovering novel neuropathic pain therapeutic mechanisms to develop the next generation of non-addictive agents for neuropathic pain; an unrelenting nerve pain with huge unmet medical need.
Stimuli-Selective Antibodies Against hTRPV1
Sharing insights from the AbiProt antibody platform to develop functional antibodies targeting ion channels Maximizing pain relief through inhibition of TRPV1 channel with mAbs Circumventing side effects associated with previous small molecule antagonists
